Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Amerisource Health Services LLC

Amerisource Health Services LLC Recalls

All product recalls associated with Amerisource Health Services LLC.

Get alerts for this brand

Recall Summary

Total Recalls

Past Year

Class I (Serious)

Most Recent

Oct 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 21–40 of 65 recalls

Duloxetine Capsules 60mg (Amerisource) – CGMP Impurity Limit (2024)

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Class IIModerate

FDADec 6, 2024Nationwide• Amerisource Health Services LLC

Duloxetine Capsules 30mg (Amerisource) – CGMP Impurity Limit (2024)

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit.

Class IIModerate

FDADec 6, 2024Nationwide• Amerisource Health Services LLC

Duloxetine Capsules 60 mg (Amerisource) – Impurity Concern (2024)

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

123 4

Page 2 of 4Next

Class II

Moderate

FDANov 14, 2024OH, PA, PR• Amerisource Health Services LLC

Duloxetine Capsules 30 mg (Amerisource) – Impurity Concern (2024)

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

Class IIModerate

FDANov 14, 2024OH, PA, PR• Amerisource Health Services LLC

Duloxetine Capsules (Amerisource) – Impurity Limit Exceeded (2024)

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

Class IIModerate

FDANov 14, 2024OH, PA, PR• Amerisource Health Services LLC

Potassium Chloride Capsules (Amerisource) – Dissolution Failure (2024)

Failed Dissolution Specifications

Class IHigh

FDAJun 25, 2024Nationwide• Amerisource Health Services LLC

Bupropion Extended-Release Tablets (Amerisource) – Dissolution Issue (2024)

Failed Dissolution Specifications; the product is dissolving faster than the specified limits.

Class IIModerate

FDAJun 24, 2024Nationwide• Amerisource Health Services LLC

HydrALAZINE Tablets (Amerisource) – Impurities Specification (2024)

Failed Impurities/Degradation Specifications: Out of Specification (OOS) result in the repackaged product for Related Compounds (Impurities) at the 6-month time point.

Class IIILow

FDAFeb 1, 2024Nationwide• Amerisource Health Services LLC

Febuxostat Tablets (Amerisource) – CGMP Deviation (2024)

CGMP Deviations

Class IIModerate

FDAJan 25, 2024Nationwide• Amerisource Health Services LLC

Rifampin Capsules (Amerisource) – Failed Impurities (2024)

Failed Impurities/Degradation Specification.

Class IIModerate

FDAJan 11, 2024Nationwide• Amerisource Health Services LLC

Benzonatate Capsules (Amerisource) – Superpotent Drug (2023)

Superpotent drug: Assay results were slightly above specification at the time zero point.

Class IIILow

FDADec 26, 2023Nationwide• Amerisource Health Services LLC

HydrALAZINE Hydrochloride Tablets (Amerisource) – impurity specification (2023)

Failed Impurities/Degradation Specifications: Out of Specification results in the repackaged product for impurities at the 12-month time point.

Class IIILow

FDASep 1, 2023Nationwide• Amerisource Health Services LLC

Tizanidine 4mg Tablets (Amerisource) – Dissolution Specifications (2023)

Failed Dissolution Specifications: this repackaged product was recalled by the manufacturer, Dr. Reddy's Laboratories, Inc., due to out of specification results for dissolution.

Class IIModerate

FDAJun 23, 2023Nationwide• Amerisource Health Services LLC

Glimepiride Tablets (Amerisource Health Services) – Manufacturing Deviation (2023)

CGMP Deviations: recalling drug products following an FDA inspection.

Class IIModerate

FDAMar 17, 2023Nationwide• Amerisource Health Services LLC

Glimepiride 4mg Tablets (Amerisource) – Manufacturing Deviation (2023)

CGMP Deviations: recalling drug products following an FDA inspection.

Class IIModerate

FDAMar 17, 2023Nationwide• Amerisource Health Services LLC

Glimepiride Tablets (Amerisource Health Services) – Manufacturing Deviation (2023)

CGMP Deviations: recalling drug products following an FDA inspection.

Class IIModerate

FDAMar 17, 2023Nationwide• Amerisource Health Services LLC

Verapamil Tablets (Amerisource Health Services) – Dissolution Specification Failure (2023)

Failed Dissolution Specifications: Out of specification dissolution results above specified values.

Class IIModerate

FDAMar 16, 2023Nationwide• Amerisource Health Services LLC

Verapamil Hydrochloride Tablets (Amerisource) - Failed Dissolution (2023)

Failed Dissolution Specification: Out of specification dissolution results at time point zero. The OOS was above specified values.

Class IIModerate

FDAJan 27, 2023Nationwide• Amerisource Health Services LLC

Metoprolol Succinate Tablets (Amerisource) - Dissolution Failure (2023)

Failed Dissolution Specifications: This recall is being initiated in support of the recall by the manufacturer which included lots that were packaged for BluePoint Laboratories.

Class IIModerate

FDAJan 11, 2023Nationwide• Amerisource Health Services LLC

Bupropion Hydrochloride 75MG (Amerisource) – Impurity Risk (2022)

Failed Impurities/Degradation Specifications

Class IIModerate

FDADec 27, 2022Nationwide• Amerisource Health Services LLC